BioCardia, Inc. (BCDA): Operating Income
-$8.28M
Year ended 2025-12-31
-$7.39M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$8.28M | n/m | 2026-03-24, From 2025-01-01 |
| 2024-12-31 | -$8.00M | n/m | 2026-03-24, From 2024-01-01 |
| 2023-12-31 | -$11.64M | n/m | 2025-03-26, From 2023-01-01 |
| 2022-12-31 | -$11.90M | n/m | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | -$12.63M | n/m | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | -$15.53M | n/m | 2022-03-29, From 2020-01-01 |
| 2019-12-31 | -$14.21M | n/m | 2021-03-30, From 2019-01-01 |
| 2018-12-31 | -$14.10M | n/m | 2020-04-09, From 2018-01-01 |
| 2017-12-31 | -$12.40M | n/m | 2020-04-09, From 2017-01-01 |
| 2016-12-31 | -$7.61M | n/m | 2019-04-02, From 2016-01-01 |
| 2015-12-31 | -$5.41M | n/m | 2018-03-16, From 2015-01-01 |
| 2014-12-31 | $231.0K | n/m | 2016-03-25, From 2014-01-01 |
| 2013-12-31 | $9.0K | n/m | 2015-03-24, From 2013-01-01 |
| 2012-12-31 | -$339.0K | n/m | 2014-03-24, From 2012-01-01 |
| 2011-12-31 | -$618.0K | n/m | 2013-03-22, From 2011-01-01 |
| 2010-12-31 | -$583.0K | n/a | 2012-03-29, From 2010-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | 2025-12-31 | -$8.28M | n/m |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $18.07M | n/m |
| Amgen Inc (AMGN) | 2025-12-31 | $9.08B | +25.1% |
| Repligen Corp (RGEN) | 2025-12-31 | $55.17M | n/m |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | -$1.14M | n/m |
| Bio-Techne Corp (TECH) | 2026-06-30 | $251.89M | +146.3% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | -$36.62M | n/m |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $10.02B | +503.0% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $340.99M | n/m |
Compare BCDA, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗